Pharmafocus Home
    
Keyword Search
Go News Archive Features Events Appointments Jobs Contact Us About Us
Latest Features ( May )
Should I stay or should I go?
There are no easy answers when it comes to timing a job move, says Tim Ewbank, but you can make yourself a more attractive candidate for that next job.(more)
Regional research still hampered by cross-border differences
In the age of the Euro-trial, patients are not well served by processes that add unnecessary delays to the development of new medicines, says Les Rose(more)
A sea of paperwork or business as usual?
Steven Gray looks ahead to the soon-to-be finalised 2008 ABPI Code of Practice and how it will affect everyday practice in the UK industry(more)
PharmafocusNews Register for New Alert
News for July 2004
Previous Months: April 2008 |  March 2008 |  February 2008 |  January 2008 |  December 2007 |  November 2007 |  October 2007 |  September 2007 |  August 2007 |  July 2007 |  June 2007 |  May 2007 |  April 2007 |  March 2007 |  February 2007 |  January 2007 |  December 2006 |  November 2006 |  October 2006 |  September 2006 |  August 2006 |  July 2006 |  June 2006 |  May 2006 |  April 2006 |  March 2006 |  February 2006 |  January 2006 |  December 2005 |  November 2005 |  October 2005 |  September 2005 |  August 2005 |  July 2005 |  June 2005 |  May 2005 |  April 2005 |  March 2005 |  February 2005 |  January 2005 |  December 2004 |  November 2004 |  October 2004 |  September 2004 |  August 2004 |  July 2004 |  June 2004 |  May 2004 |  April 2004 |  March 2004 |  February 2004 |  January 2004 |  December 2003 |  November 2003 |  October 2003 |  September 2003 |  August 2003 |  July 2003 |  June 2003 |  May 2003 |  April 2003 |  March 2003 |  February 2003 |  January 2003 |  December 2002 |  November 2002 | 

  What is RSS?

Pharma defies extremists with £4 million animal research fund
Grants to be given to universities..(more)

 R&D chief loses his cool over Swedish attitude
AstraZeneca committed to Sweden..(more)

 'Patents versus patients' still part of the problem
Collaborative effort required..(more)

 Vytorin poised to benefit from controversial US guidelines
New guidelines questioned..(more)

 Targets out and standards in for next NHS three-year plan
Quality of care to be raised..(more)

 Merck enlist Avenue for Erbitux launch
Avenue selected after five-way pitch..(more)

 Falling stars blight NHS performance ratings
Mental health trusts underperform..(more)

 Half a million asthma patients suffering unnecessarily
Asthma UK survey highlights problems..(more)

 Embarrassing problem to become marketing battleground
Four new products prepare for launch..(more)

 Pfizer seizes initiative with US drug discount programme
Pfizer offers drug discounts to uninsured..(more)

 Vaccine to help smokers kick the habit shows promise
Xenova gets share boost..(more)

 Framework to promote pharma-NHS partnerships launched
ABPI points to partnership benefits..(more)

 AstraZeneca appoints new global head of product PR
Exanta roll-out a major challenge..(more)

 Lilly's 'Cialis Promise' increases pressure on Viagra
Consumer-style tactics increasing..(more)

 Atacand filed for heart failure in US
Atacand to take on Novartis' Diovan..(more)

 Pfizer UK recruiting for new customer-focused salesforce
Company aligns salesforce to PCO boundaries..(more)

 Severe asthma treatment Xolair filed in Europe
NICE to finish appraisal in 2006..(more)

 Pfizer's next blockbuster Lyrica receives European approval
New drug receives two licences..(more)

 Labour stakes its reputation on NHS Plan part II
Improvement Plan pledges made..(more)

 Growing doubts over reliability of HRT trial conclusions
Yale researchers say trial may be flawed..(more)

 Takeda to launch 'radically different' approach to NHS
Autonomous regional account managers planned..(more)

 Sanofi executives take control of new boardroom
Sanofi to hold key positions ..(more)

 US parallel trade to be legalised after Republican U-turn
EU could benefit from legislation..(more)

 Novartis rivals find VALUE in landmark Diovan trial
Trial disappointing for Novartis..(more)

 Fast4wD expands clinical trial focus
Merged company offers global services..(more)

 Second wave of foundation hospitals approved
Ten more NHS trusts approved..(more)

 Pharma's reputation continues to slide
Poll results support re-importation..(more)

Are you a Pharmafocus subscriber?

Subscribe Now 

Visit our sister sites: 

InPharm.com 

Pharmafile.com 

Pharmafocus.com © 2006 Pharmafile Ltd.